Mylan Pharmaceuticals Inc., Breckenridge Pharmaceutical Inc. and APP Pharmaceuticals have received approval from the Food and Drug Administration to offer anastrozole tablets, a treatment for early breast cancer.


anastrozole, anastrozole generic, Arimidex, Mylan Pharmaceuticals, Breckenridge Pharmaceutical, APP Pharmaceuticals, early breast cancer, anastrozole tablets, AstraZeneca, Food and Drug Administration








































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Pharma firms cleared to market anastrozole generic

June 29th, 2010

NEW YORK – Mylan Pharmaceuticals Inc., Breckenridge Pharmaceutical Inc. and APP Pharmaceuticals have received approval from the Food and Drug Administration to offer anastrozole tablets, a treatment for early breast cancer.

The companies said Tuesday they plan to market 1 mg anastrozole tablets. The medication is the generic version of AstraZeneca's Arimidex tablets.

Citing IMS Health data, Mylan reported that anastrozole tablets has U.S. sales of about $917 million for the 12 months ended March 31. APP Pharmaceuticals said the drug had 2009 sales of approximately $916.8 million, with about 105 million tablets sold annually, according to IMS data.

All three companies said they plan to make the anastrozole tablets available immediately.

Advertisement